共 238 条
[1]
Boaz MJ(2009)Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents Clin Vaccine Immunol 16 147-155
[2]
Hayes P(2003)Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the third immunology of diabetes society T-cell workshop J Autoimmun 21 365-376
[3]
Tarragona T(2000)Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial J Immunol Methods 244 81-89
[4]
Seamons L(2009)Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis PLoS ONE 4 e7972-81
[5]
Cooper A(2005)Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials AIDS Res Hum Retroviruses 21 68-627
[6]
Birungi J(2010)Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program Cancer Immunol Immunother 59 619-315
[7]
Kitandwe P(2008)Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI) Cancer Immunol Immunother 57 303-627
[8]
Semaganda A(2013)Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols Cancer Immunol Immunother 62 615-618
[9]
Kaleebu P(2010)Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells Cancer Immunol Immunother 59 609-1713
[10]
Stevens G(2009)Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium Cancer Immunol Immunother 58 1701-302